DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Space Economy · $ASTS · $RKLB · $SPCE · $FJET
Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared
A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and space systems ($RKLB), suborbital tourism ($SPCE), and supersonic flight-testing / air-launch infrastructure ($FJET), after the record SpaceX IPO and the sector’s sharp repositioning.
Next sector catalyst
2H 2026 — Rocket Lab Neutron debut remains targeted for Q4 2026
Other upcoming events
Virgin Galactic: Delta-class flight testing in Q3 2026 and first spaceflight targeted for Q4 2026 · AST SpaceMobile: BlueBird satellite/gateway ramp and commercial/government revenue execution · Starfighters Space: STARLAUNCH and hypersonic-testing progress.
Executive summary
The publicly traded “space economy” is not a single, homogeneous theme: within the same narrative live radically different business models, with cash, risk and maturity profiles that sit at opposite ends of the spectrum. This report compares four names that represent four distinct bets on space: AST SpaceMobile ($ASTS), Rocket Lab ($RKLB), Virgin Galactic ($SPCE) and Starfighters Space ($FJET).
The 2026 backdrop changed materially with the record SpaceX IPO, which brought enormous capital and media attention back to the sector but also triggered a repositioning: after the initial enthusiasm, several “space” names saw a sell-off, with brokerage houses openly discussing bearish trades on the group. In this climate, the difference between companies with real revenue and a solid cash position and those still pre-revenue becomes decisive.
Rocket Lab is the most mature name here: record quarterly revenue (about $200 million in Q1 2026, +63.5% year-over-year), a $2.2 billion backlog and the Neutron rocket due to debut by the end of 2026. AST SpaceMobile is the “infrastructure” bet on satellite-to-phone: a huge cash pile (about $3.5 billion) but still minimal revenue and a model yet to be proven at commercial scale. Virgin Galactic is the suborbital tourism story, with its new Delta-class vehicles coming but a fragile cash position and a “going concern” flag in its 10-K. Starfighters Space is the smallest, most speculative name: pre-revenue, built on a fleet of F-104 supersonic jets and the STARLAUNCH air-launch platform.
The purpose of this article is strictly informational: to compare business models, verified numbers, catalysts and risks, and to outline illustrative bull and bear sector scenarios — without making any buy or sell recommendation.
Sources (Executive summary): SEC Form 8-K Q1 2026 for AST SpaceMobile and Rocket Lab; Virgin Galactic FY2025/Q1 2026 results; Starfighters Space filings and press releases; Reuters coverage of the SpaceX IPO, company investor-relations releases, SEC filings and market data. Specific links in each section below.
Quick snapshot (as of 26 June 2026)
$ASTS · Price
$71.45
Market cap ≈ $21B
Cash ≈ $3.5B (Q1’26)
Cash ≈ $3.5B (Q1’26)
$RKLB · Price
$84.54
Market cap ≈ $51.2B
Cash $1.48B (Q1’26)
Cash $1.48B (Q1’26)
$SPCE · Price
$2.95
Market cap ≈ $234M
Cash & marketable securities $251M (Q1’26)
Cash & marketable securities $251M (Q1’26)
$FJET · Price
$5.40
Market cap ≈ $238M
Pre-revenue · cash/restricted cash $2.14M (Q1’26) · $17.5M raise (May’26)
Pre-revenue · cash/restricted cash $2.14M (Q1’26) · $17.5M raise (May’26)
| Stock | Exchange | Segment | Stage | Key catalyst |
|---|---|---|---|---|
| $ASTS — AST SpaceMobile | NASDAQ | Satellite-to-phone broadband (BlueBird) | Early revenue, infrastructure deploy | Gateway/satellite ramp, MNO & US gov partners |
| $RKLB — Rocket Lab | NASDAQ | Launch (Electron/Neutron) + Space Systems | Fast-growing revenue | Neutron debut (Q4 2026 target) |
| $SPCE — Virgin Galactic | NYSE | Suborbital tourism (Delta-class) | Pre-commercial revenue, cash burn | Delta testing Q3 2026 · first spaceflight Q4 2026 |
| $FJET — Starfighters Space | NYSE American | Supersonic flight-testing + air-launch (STARLAUNCH) | Pre-revenue (R&D) | STARLAUNCH progress, hypersonic partnerships |
Sources (Snapshot): prices and market caps from market data as of the 26 June 2026 close; cash and balance-sheet data from the company filings and investor-relations releases cited below. Market caps are indicative and subject to high daily volatility.
The backdrop: space economy after the SpaceX IPO
For years, a “pure” space investment was hard to find for retail investors: listed names were few and often the legacy of disappointing SPACs. In 2026 the SpaceX listing changed the perception of the sector, attracting capital and fresh analyst coverage. The effect, however, cut both ways: after the initial euphoria, several space names (including $ASTS, $RKLB, $SPCE and others) saw profit-taking, and some investment houses began openly discussing bearish “betting against space” trades.
Against this backdrop, the four stocks analyzed here let you read the sector along two axes: revenue maturity (from Rocket Lab, with hundreds of millions in revenue, to Starfighters, still pre-revenue) and type of exposure (telecom infrastructure, space access, experience/tourism, testing services). They are four different ways to “buy space,” with very different risk levels.
The four business models compared
$ASTS — AST SpaceMobile: a cellular network from space
AST SpaceMobile aims to build the first cellular broadband network accessible directly from standard smartphones via satellites (the “BlueBirds”), in partnership with mobile operators such as AT&T, Verizon and Vodafone, plus the US government. It is a highly capital-intensive infrastructure bet: in February 2026 the company raised about $1.075 billion via 10-year convertible notes with a 2.250% coupon, bringing total cash to roughly $3.5 billion (including $429.3 million of restricted cash) at the end of March 2026. The current weak spot is revenue: Q1 2026 came in at $14.7 million (below expectations), while full-year 2026 guidance is $150–200 million, driven by network partners and government contracts.
$RKLB — Rocket Lab: the most mature launch company in the group
Rocket Lab has the strongest fundamentals of the four. In Q1 2026 it posted record revenue of about $200.3 million (+63.5% year-over-year), a $2.2 billion backlog (+20% quarter-over-quarter) and a record GAAP gross margin of 38.2%. Cash at quarter-end was $1.48 billion, with over $2 billion in total liquidity. The model combines the small Electron launcher (50+ successful launches), the Space Systems segment (satellites and components) and, above all, the medium-lift Neutron rocket, whose debut is expected by the end of 2026 and which has already secured launch contracts before flying.
$SPCE — Virgin Galactic: suborbital tourism tested by the balance sheet
Virgin Galactic sells the suborbital flight experience to tourists and for scientific research. After pausing commercial flights to focus on its new Delta-class vehicles — designed for more frequent flights (high-frequency operations once the Delta fleet is built and cleared) — the company said it remains on track for Delta-class flight testing in Q3 2026 and its first spaceflight in Q4 2026. The crux is financial: cash, cash equivalents and marketable securities were $251 million as of 31 March 2026, with negative free cash flow of about $78 million in Q1 2026 and a “going concern” flag in the 10-K. It is the most binary story from a balance-sheet standpoint.
$FJET — Starfighters Space: supersonic testing and air-launch
Starfighters Space is the smallest, most speculative name. Based at NASA’s Kennedy Space Center, it operates the only commercial fleet of Lockheed F-104 supersonic jets, offering Mach 2+ flight testing, pilot training and air-launch services. The company is still pre-revenue: Q1 2026 showed nil revenue, operating expenses of about $4.05 million, a net loss of about $4.27 million, and cash plus restricted cash of $2.14 million at March 31, 2026. In May 2026 it announced a $17.5 million strategic equity investment to support expansion and the STARLAUNCH air-launch platform. The stock remains extremely volatile, especially after the December 2025 spike and June 2026 pullback.
Sources (Business models): $ASTS Q1 2026 8-K (SEC); Rocket Lab Q1 2026 results; Virgin Galactic Q1 2026 results; Starfighters Space Q1 2026 Form 10-Q release.
Comparative financial position
| Item | $ASTS | $RKLB | $SPCE | $FJET |
|---|---|---|---|---|
| Cash (latest) | ≈ $3.5B (Q1’26) | $1.48B (Q1’26) | $251M (Q1’26) | Cash/restricted cash $2.14M (Q1’26) · $17.5M raise |
| Revenue (latest qtr) | $14.7M (Q1’26) | $200.3M (Q1’26) | Pre-commercial revenue | $0 (Q1’26) |
| Revenue growth | FY26 guidance $150–200M | +63.5% YoY | n/a (flights paused) | n/a |
| Backlog / liquidity | $1.075B converts (Feb’26) | Backlog $2.2B · liquidity >$2B | Q1’26 FCF ≈ -$78M | Q1’26 net loss $4.27M |
| Balance-sheet signal | Very high cash, revenue to prove | Strongest profile of the group | “Going concern” flag in 10-K | Pre-revenue micro-cap, high dilution risk |
How to read these numbers
Cash should always be weighed against burn rate and the capital needs of the model. AST SpaceMobile has the largest cash pile but also one of the heaviest capex plans (a satellite constellation). Rocket Lab is the only one with revenue growing at double/triple digits and expanding gross margins. Virgin Galactic and Starfighters depend more directly on capital markets to fund development, which raises dilution risk, especially after a negative catalyst.
Sources (Finance): Q1 2026 SEC filings and company releases for $ASTS, $RKLB, $SPCE and $FJET. Cash, revenue, backlog and burn figures are shown as of the dates indicated.
Catalysts and timeline
- $$RKLB — Neutron debut (Q4 2026 target): first flight of the medium-lift rocket, with contracts already signed pre-launch. The most anticipated catalyst in the group.
- $$SPCE — Delta-class flights: Delta-class flight testing remains targeted for Q3 2026, with the first spaceflight targeted for Q4 2026; commercial service start remains the next major milestone.
- $$ASTS — Infrastructure ramp: deploying BlueBird gateways and satellites, activating services with mobile partners and US government contracts; the FY26 revenue guidance ($150–200M) is the execution thermometer.
- $$FJET — STARLAUNCH and partnerships: progress on the air-launch platform and potential hypersonic testing deals; deployment of the capital raised in May 2026.
- Sector — SpaceX effect: post-IPO sentiment around SpaceX remains a cross-cutting factor that can amplify moves across the whole group.
Illustrative sector scenarios (not recommendations)
Bull scenario
- Neutron debuts successfully, reinforcing Rocket Lab’s leadership in space access and the conversion of backlog into revenue.
- AST SpaceMobile accelerates deployment and signs/activates revenue with mobile partners and the US government, validating the satellite-to-phone model.
- Virgin Galactic keeps Delta-class testing and Q4 spaceflight timing on schedule, reopening the suborbital tourism revenue stream.
- Post-SpaceX sector sentiment stabilizes and again rewards names with credible execution.
Bear scenario
- Delays on Neutron or the Delta-class push revenue further out and cool expectations.
- AST SpaceMobile revenue stays below guidance, pressuring a stock with a high valuation relative to current sales.
- Virgin Galactic must raise new capital on unfavorable terms (going-concern flag), with significant dilution.
- “Betting against space” becomes the dominant narrative and compresses multiples across the group, hitting pre-revenue names like $FJET hardest.
Risks and red flags
- Execution/technology risk: launches, flights and space deployments are inherently binary; delays or technical failures can push revenue out by quarters or years.
- Dilution risk: $SPCE and $FJET depend on capital markets; raises after negative catalysts can be highly dilutive. $ASTS has already issued sizable convertibles.
- Valuation risk: some names (notably $ASTS and $RKLB) trade at high multiples relative to current revenue; a shift in sentiment can amplify corrections.
- Going concern ($SPCE): the 10-K flag signals uncertainty about continuity without new capital.
- Liquidity and volatility ($FJET): pre-revenue micro-cap with extreme swings (recent trading range remains extremely volatile after the December 2025 spike and June 2026 pullback).
- Sector/sentiment risk: the SpaceX effect and bearish sector trades can move all names regardless of individual fundamentals.
Bottom line
Side by side, the four stocks show how heterogeneous the “space economy” really is. Rocket Lab is the most mature profile by revenue, backlog and cash, with a clear catalyst (Neutron). AST SpaceMobile is the highest-capital, highest-cash infrastructure bet, but with revenue still to be built. Virgin Galactic is the story most tied to a return to flight and balance-sheet resilience. Starfighters Space is the smallest, most speculative option, still pre-revenue. Each answers a different risk profile and time horizon: the point of this comparison is not to crown a “winner,” but to clarify exactly what you are buying in each of the four cases.
Disclaimer (EN): this content is for educational and informational purposes only. It does not constitute financial advice, an investment recommendation or a solicitation to buy or sell any security, consistent with CONSOB (Italy) and SEC (US) guidelines. The information summarized here is based on publicly available sources believed to be reliable (SEC filings, official press releases, major newswires), but no representation or warranty is made as to its completeness or accuracy. All scenarios, estimates and interpretations are inherently uncertain and subject to change without notice. Prices and market caps are indicative as of the date cited and change constantly.
Readers should perform their own independent research and, where appropriate, consult a licensed financial advisor before making any investment decision. Full disclaimer: merlintrader.com/disclaimer.
Catalyst Calendar
Want a cleaner view of the next major US market catalysts across space, biotech, launches, filings, clinical dates and earnings events? Open the Merlintrader Catalyst Calendar and track what could move next.
Open the Catalyst Calendar

